Realistic depiction of GluD2 glutamate receptor activating as an ion channel via D-serine and GABA, with Johns Hopkins neuroscientists in a lab setting.
AI:n luoma kuva

Johns Hopkins team finds delta-type glutamate receptors function as ligand-gated ion channels

AI:n luoma kuva
Faktatarkistettu

Johns Hopkins Medicine researchers report that delta-type ionotropic glutamate receptors (GluDs)—long debated as to whether they conduct ions—can act as ligand-gated ion channels. The Nature study used cryo-electron microscopy and membrane recording experiments to characterize human GluD2 and found it can be activated by the neurotransmitters D-serine and GABA, findings the authors say could help guide drug development for disorders linked to GluD mutations.

Researchers at Johns Hopkins Medicine say they have clarified the long-standing question of whether delta-type ionotropic glutamate receptors, known as GluDs, can function as ion channels.

In a paper published in Nature, the team reports that purified human GluD2 (hGluD2) behaves as a ligand-gated ion channel in vitro. The researchers used cryo-electron microscopy alongside membrane electrical recording experiments to characterize the receptor’s structure and channel activity.

“This class of protein has long been thought to be sitting dormant in the brain,” said Edward Twomey, Ph.D., an assistant professor of biophysics and biophysical chemistry at the Johns Hopkins University School of Medicine, according to a Johns Hopkins Medicine release carried by ScienceDaily.

The study reports that hGluD2 can be activated by the neurotransmitters D-serine and GABA, and that activation is stronger at physiological temperatures. The authors also describe how the receptor’s ligand-binding domains are coupled to an ion channel pore, providing a structural explanation for how binding can trigger channel opening.

The researchers also examined a cerebellar ataxia–linked point mutation in the ligand-binding domain and report that it alters receptor architecture and can produce so-called “leak” currents in their experiments.

Johns Hopkins Medicine said the findings may help inform efforts to design drugs that modulate GluD activity in disorders associated with GluD mutations, including psychiatric conditions such as anxiety and schizophrenia, and neurological disorders affecting movement.

The Nature article lists Haobo Wang, Fairine Ahmed, Jeffrey Khau, and Anish Kumar Mondal as co-authors with Twomey. ScienceDaily, citing Johns Hopkins Medicine materials, also reports that Johns Hopkins University has filed a patent covering techniques used to measure electrical currents from GluDs and that the work was funded by the National Institutes of Health, the Searle Scholars Program, and the Diana Helis Henry Medical Research Foundation.

The paper is titled “Delta-type glutamate receptors are ligand-gated ion channels” and appears in Nature (volume 647, issue 8091, pages 1063–1071; published online Sept. 16, 2025; issue date Nov. 27, 2025).

Liittyvät artikkelit

Illustration of mouse exhibiting depression and anxiety behaviors due to disrupted ATP signaling and connexin 43 in dorsal hippocampus brain region.
AI:n luoma kuva

Study links disrupted brain energy signaling to depression- and anxiety-like behaviors in mice

Raportoinut AI AI:n luoma kuva Faktatarkistettu

Researchers report that reduced ATP signaling in the dorsal hippocampus of male mice, driven by changes in the protein connexin 43, can trigger both depression- and anxiety-like behaviors. The study, published in The Journal of Neuroscience, finds that chronic stress lowers extracellular ATP and connexin 43 levels, that experimentally reducing the protein induces similar behaviors even without stress, and that restoring it in stressed animals improves behavioral signs of distress.

Researchers have engineered a protein that detects subtle glutamate signals between neurons, unveiling a previously hidden aspect of brain communication. This tool allows real-time observation of how brain cells process incoming information, potentially advancing studies on learning, memory, and neurological disorders. The findings, published in Nature Methods, highlight a breakthrough in neuroscience.

Raportoinut AI

Researchers have uncovered how amyloid beta and inflammation may both trigger synapse pruning in Alzheimer's disease through a common receptor, potentially offering new treatment avenues. The findings challenge the notion that neurons are passive in this process, showing they actively erase their own connections. Led by Stanford's Carla Shatz, the study suggests targeting this receptor could preserve memory more effectively than current amyloid-focused drugs.

Weill Cornell Medicine researchers report that free radicals generated at a specific mitochondrial site in astrocytes appear to promote neuroinflammation and neuronal injury in mouse models. Blocking those radicals with tailored compounds curbed inflammation and protected neurons. The findings, published Nov. 4, 2025, in Nature Metabolism, point to a targeted approach that could inform therapies for Alzheimer’s disease and frontotemporal dementia.

Raportoinut AI Faktatarkistettu

Washington University scientists report that inhibiting the circadian regulator REV-ERBα raised brain NAD+ and reduced tau pathology in mouse models, pointing to a clock-focused strategy worth exploring for Alzheimer’s disease.

Researchers at Washington University School of Medicine in St. Louis, working with scientists at Northwestern University, have developed a noninvasive nasal nanotherapy that activates the immune system to attack aggressive brain tumors in mice. By delivering spherical nucleic acids that trigger the STING immune pathway directly from the nose to the brain, the approach eliminated glioblastoma tumors in mouse models when combined with drugs that boost T-cell activity, according to a study in the Proceedings of the National Academy of Sciences.

Raportoinut AI

Researchers at UNSW Sydney have identified around 150 functional DNA enhancers in human astrocytes that regulate genes associated with Alzheimer's disease. By testing nearly 1,000 potential switches using advanced genetic tools, the team revealed how non-coding DNA influences brain cell activity. The findings, published on December 18 in Nature Neuroscience, could aid in developing targeted therapies and improving AI predictions of gene control.

 

 

 

Tämä verkkosivusto käyttää evästeitä

Käytämme evästeitä analyysiä varten parantaaksemme sivustoamme. Lue tietosuojakäytäntömme tietosuojakäytäntö lisätietoja varten.
Hylkää